These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37006779)

  • 21. Changes in the Etiologies of Liver Cancer in Upper Egypt over a Decade from 2010 to 2020: A Single Tertiary Care Center Study.
    Fouad Y; Gaber Y; Alem SA; Abdallah M; Abd-Elsalam SM; Nafady S; Attia D; Eslam M
    South Asian J Cancer; 2024 Jan; 13(1):10-16. PubMed ID: 38721105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection.
    Lin YP; Lin SH; Wang CC; Lin CC; Chen DW; Chuang CH; Huang PY; Hung CH; Yang SY; Cho WR; Chen YS; Tsai MC
    J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.
    Xue J; Wang QX; Xiao HM; Shi MJ; Xie YB; Li S; Lin M; Chi XL
    Cancer Manag Res; 2022; 14():2193-2202. PubMed ID: 35859711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease.
    Lu H; George J; Eslam M; Villanueva A; Bolondi L; Reeves HL; McCain M; Chambers E; Ward C; Sartika D; Sands C; Maslen L; Lewis MR; Ramaswami R; Sharma R
    Liver Cancer; 2023 Feb; 12(1):19-31. PubMed ID: 36872928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.
    Kawaguchi T; Tsutsumi T; Nakano D; Eslam M; George J; Torimura T
    Clin Mol Hepatol; 2022 Apr; 28(2):150-163. PubMed ID: 34753279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MAFLD-related hepatocellular carcinoma: Exploring the potent combination of immunotherapy and molecular targeted therapy.
    Guo Z; Yao Z; Huang B; Wu D; Li Y; Chen X; Lu Y; Wang L; Lv W
    Int Immunopharmacol; 2024 Oct; 140():112821. PubMed ID: 39088919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease.
    Yoo JJ; Park MY; Cho EJ; Yu SJ; Kim SG; Kim YJ; Kim YS; Yoon JH
    J Clin Med; 2023 May; 12(9):. PubMed ID: 37176776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease.
    Lin H; Zhang X; Li G; Wong GL; Wong VW
    J Clin Transl Hepatol; 2021 Dec; 9(6):972-982. PubMed ID: 34966660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy.
    Guo F; Estévez-Vázquez O; Benedé-Ubieto R; Maya-Miles D; Zheng K; Gallego-Durán R; Rojas Á; Ampuero J; Romero-Gómez M; Philip K; Egbuniwe IU; Chen C; Simon J; Delgado TC; Martínez-Chantar ML; Sun J; Reissing J; Bruns T; Lamas-Paz A; Moral MGD; Woitok MM; Vaquero J; Regueiro JR; Liedtke C; Trautwein C; Bañares R; Cubero FJ; Nevzorova YA
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study.
    Chen YG; Yang CW; Chung CH; Ho CL; Chen WL; Chien WC
    Hepatol Int; 2022 Aug; 16(4):807-816. PubMed ID: 35064545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study.
    Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink.
    Fernandez CJ; Alkhalifah M; Afsar H; Pappachan JM
    Pathogens; 2024 Jan; 13(1):. PubMed ID: 38251375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
    Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
    Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.
    Loomba R; Lim JK; Patton H; El-Serag HB
    Gastroenterology; 2020 May; 158(6):1822-1830. PubMed ID: 32006545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis.
    Wang X; Xie Q
    J Clin Transl Hepatol; 2022 Feb; 10(1):128-133. PubMed ID: 35233381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review.
    Ismaiel A; Dumitrascu DL
    Eur J Clin Invest; 2020 Oct; 50(10):e13331. PubMed ID: 32589269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians.
    Cespiati A; Cinque F; Meroni M; Lombardi R; Dongiovanni P; Fracanzani AL
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.